The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2021 | MRD assessment for surveillance post-treatment in DLBCL
Anita Kumar, MD, Memorial Sloan Kettering, Short Hills, NJ, discusses monitoring minimal residual disease (MRD) to detect molecular relapse in patients with diffuse large B-cell lymphoma (DLBCL). 400 patients treated with R-CHOP were assessed every three months, with a computerized tomography (CT) scan every six months for two years. MRD assays failed to accurately detect molecular relapse in patients, with false positives reported in a subset of patients. However, cases of asymptomatic relapse were able to be identified with CT imaging. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
